UCART123

BIOLOGICAL2 trials

Sponsors

Cellectis S.A.

Conditions

Acute Myeloid LeukaemiaBlastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)

Phase 1

Study to Evaluate the Safety and Clinical Activity of UCART123 in Patients With BPDCN

TerminatedNCT03203369

Cellectis S.A.Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)

Start: 2017-06-28End: 2019-06-27Updated: 2019-07-31

Phase I Study of UCART123 in Patient With Adverse Genetic Risk Acute Myeloid Leukemia

WithdrawnNCT04106076

Cellectis S.A.Acute Myeloid Leukaemia

Start: 2019-07-11End: 2019-12-05Updated: 2020-07-14

Related Papers

Glucose transporter 5 enhances CAR-T cell metabolic function and serial killing

Blood2025-11-03

Ameli-01: A Phase I Trial of UCART123v1.2, an Anti-CD123 Allogeneic CAR-T Cell Product, in Adult Patients with Relapsed or Refractory (R/R) CD123+ Acute Myeloid Leukemia (AML)

Blood2022-11-1560 citations

Global Perspective on the Development of Genetically Modified Immune Cells for Cancer Therapy.

2021-02-156 citations

Abstract 2560: Preclinical efficacy of allogeneic anti-CD123 CAR T-cells for the therapy of blastic plasmacytoid dendritic cell neoplasm (BPDCN)

Cancer Research2018-07-012 citations